Laddar...
NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Anti-PD1 and anti-PDL1 immunotherapy has transformed urothelial carcinoma treatment. Pembrolizumab is the only immunotherapy agent shown to have survival benefit compared with standard chemotherapy after progression on platinum-containing chemotherapy. Initial National Institute for Health and Care...
Sparad:
| I publikationen: | Nat Rev Urol |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338128/ https://ncbi.nlm.nih.gov/pubmed/32632305 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41585-020-0357-1 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|